Literature DB >> 18445828

Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden.

Bengt Andrae1, Levent Kemetli, Pär Sparén, Lena Silfverdal, Björn Strander, Walter Ryd, Joakim Dillner, Sven Törnberg.   

Abstract

BACKGROUND: The effectiveness of cervical cancer screening programs differs widely in different populations. The reasons for these differences are unclear. Routine and comprehensive audits have been proposed as an ethically required component of screening. We performed a nationwide audit of the effectiveness of the Swedish cervical cancer screening program.
METHODS: We identified all invasive cervical cancer cases that were diagnosed in Sweden from January 1, 1999, through December 31, 2001, and had been reported to the Swedish Cancer Registry (n = 1230 cases). We verified the diagnoses by histopathologic rereview and matched each case subject to five (population-based) age-matched control subjects who were identified from the National Population Register. The Pap smear screening histories for case and control subjects were reviewed for a 6-year period using the National Cervical Cancer Screening Register, which contains data on essentially all relevant cytological and histological diagnoses in Sweden. Odds ratios (ORs), and their 95% confidence intervals (CIs), of cervical cancer according to screening history were calculated in conditional logistic regression models. All statistical tests were two-sided.
RESULTS: Women who had not had a Pap smear within the recommended screening interval had higher risk of cervical cancer than women who had been screened (OR = 2.52, 95% CI = 2.19 to 2.91). This risk was similarly increased for all age groups (P(homogeneity) = .96). The risk for non-squamous cell cervical cancers (OR = 1.59, 95% CI = 1.20 to 2.11) was also increased. Women who had not had a Pap smear within the recommended screening interval had a particularly high risk of advanced cancers (OR = 4.82, 95% CI = 3.61 to 6.44). Among women who had been screened within the recommended interval, those with abnormal Pap smears had a higher risk of cervical cancer than those with normal smears (OR = 7.55, 95% CI = 5.88 to 9.69) and constituted 11.5% of all women with cervical cancer.
CONCLUSIONS: Nonadherence to screening intervals was the major reason for cervical cancer morbidity. The screening program was equally effective for women of all ages and was also effective against non-squamous cancers.

Entities:  

Mesh:

Year:  2008        PMID: 18445828     DOI: 10.1093/jnci/djn099

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  85 in total

1.  Cervical screening and cervical cancer death among older women: a population-based, case-control study.

Authors:  Alison S Rustagi; Aruna Kamineni; Sheila Weinmann; Susan D Reed; Polly Newcomb; Noel S Weiss
Journal:  Am J Epidemiol       Date:  2014-03-30       Impact factor: 4.897

2.  Point: cervical cancer screening guidelines should consider observational data on screening efficacy in older women.

Authors:  Alison S Rustagi; Aruna Kamineni; Noel S Weiss
Journal:  Am J Epidemiol       Date:  2013-08-21       Impact factor: 4.897

3.  Prospective study of human papillomavirus and risk of cervical adenocarcinoma.

Authors:  Lisen Arnheim Dahlström; Nathalie Ylitalo; Karin Sundström; Juni Palmgren; Alexander Ploner; Sandra Eloranta; Carani B Sanjeevi; Sonia Andersson; Thomas Rohan; Joakim Dillner; Hans-Olov Adami; Pär Sparén
Journal:  Int J Cancer       Date:  2010-10-15       Impact factor: 7.396

4.  Neither one-time negative screening tests nor negative colposcopy provides absolute reassurance against cervical cancer.

Authors:  Philip E Castle; Ana C Rodríguez; Robert D Burk; Rolando Herrero; Allan Hildesheim; Diane Solomon; Mark E Sherman; Jose Jeronimo; Mario Alfaro; Jorge Morales; Diego Guillén; Martha L Hutchinson; Sholom Wacholder; Mark Schiffman
Journal:  Int J Cancer       Date:  2009-10-01       Impact factor: 7.396

5.  Cervical cancer screening for survivors diagnosed with cancer before age 25.

Authors:  Olivia L Tseng; John J Spinelli; Martin Dawes; Mary L McBride
Journal:  J Cancer Surviv       Date:  2017-01-27       Impact factor: 4.442

6.  A first look at participation rates in cervical cancer screening programs in Canada.

Authors:  T Forte; K Decker; G A Lockwood; C M McLachlin; S Fekete; H E Bryant
Journal:  Curr Oncol       Date:  2012-10       Impact factor: 3.677

7.  Recommendations on screening for cervical cancer.

Authors:  James Dickinson; Eva Tsakonas; Sarah Conner Gorber; Gabriela Lewin; Elizabeth Shaw; Harminder Singh; Michel Joffres; Richard Birtwhistle; Marcello Tonelli; Verna Mai; Meg McLachlin
Journal:  CMAJ       Date:  2013-01-07       Impact factor: 8.262

Review 8.  How to evaluate emerging technologies in cervical cancer screening?

Authors:  Marc Arbyn; Guglielmo Ronco; Jack Cuzick; Nicolas Wentzensen; Philip E Castle
Journal:  Int J Cancer       Date:  2009-12-01       Impact factor: 7.396

9.  Self-sampling of the vaginal fluid at home combined with high-risk HPV testing.

Authors:  K Sanner; I Wikström; A Strand; M Lindell; E Wilander
Journal:  Br J Cancer       Date:  2009-08-04       Impact factor: 7.640

10.  Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data.

Authors:  Peter Sasieni; Alejandra Castanon; Jack Cuzick
Journal:  BMJ       Date:  2009-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.